Biotech Values

[DewDiligence]

Musings on ENTA’s EDP-305 NASH program:

Regrettably (IMO), ENTA is continuing the EDP-305 NASH program and intends to use doses of 1.5mg and 2.0mg in the planned phase-2b trial.

Inasmuch as the 2.5mg dose in the phase-2a trial caused undue pruritis (#msg-151356515, #msg-151358332), and the 1.0mg dose in the phase-2a trial had insufficient efficacy (as monotherapy), testing doses of 1.5mg and 2.0mg in phase-2b could be threading a needle with no eye (#msg-151358158).

If it were up to me, I would bag the EDP-305 NASH program* and move ahead full steam with EDP-297 (#msg-152423076).

With $400M in cash and no debt (#msg-152422891), ENTA need not fall prey to Zebra’s Law.

--
*EDP-305 has an in-progress phase-2 in PBC, but this trial is not costing ENTA much money.